Eloxx Pharmaceuticals (ELOX) Competitors $0.0002 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends ELOX vs. BASI, PIRS, LUNA, PGEN, AVXL, AMGN, GILD, ARGX, BIIB, and BNTXShould you be buying Eloxx Pharmaceuticals stock or one of its competitors? The main competitors of Eloxx Pharmaceuticals include Bioanalytical Systems (BASI), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Precigen (PGEN), Anavex Life Sciences (AVXL), Amgen (AMGN), Gilead Sciences (GILD), argenx (ARGX), Biogen (BIIB), and BioNTech (BNTX). Eloxx Pharmaceuticals vs. Bioanalytical Systems Pieris Pharmaceuticals Luna Innovations Precigen Anavex Life Sciences Amgen Gilead Sciences argenx Biogen BioNTech Bioanalytical Systems (NASDAQ:BASI) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership. Is BASI or ELOX more profitable? Eloxx Pharmaceuticals has a net margin of 0.00% compared to Bioanalytical Systems' net margin of -7.75%. Eloxx Pharmaceuticals' return on equity of 0.00% beat Bioanalytical Systems' return on equity.Company Net Margins Return on Equity Return on Assets Bioanalytical Systems-7.75% -42.74% -6.38% Eloxx Pharmaceuticals N/A N/A N/A Do institutionals & insiders hold more shares of BASI or ELOX? 10.6% of Bioanalytical Systems shares are owned by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 11.5% of Bioanalytical Systems shares are owned by insiders. Comparatively, 20.2% of Eloxx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, BASI or ELOX? Bioanalytical Systems has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of 2.63, meaning that its stock price is 163% more volatile than the S&P 500. Which has preferable earnings & valuation, BASI or ELOX? Bioanalytical Systems has higher revenue and earnings than Eloxx Pharmaceuticals. Bioanalytical Systems is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioanalytical Systems$60.47M0.33-$4.68M-$0.35-5.09Eloxx PharmaceuticalsN/AN/A-$36.06M-$9.070.00 Does the media refer more to BASI or ELOX? In the previous week, Bioanalytical Systems' average media sentiment score of 0.00 equaled Eloxx Pharmaceuticals'average media sentiment score. Company Overall Sentiment Bioanalytical Systems Neutral Eloxx Pharmaceuticals Neutral Does the MarketBeat Community believe in BASI or ELOX? Bioanalytical Systems received 115 more outperform votes than Eloxx Pharmaceuticals when rated by MarketBeat users. However, 43.33% of users gave Eloxx Pharmaceuticals an outperform vote while only 38.79% of users gave Bioanalytical Systems an outperform vote. CompanyUnderperformOutperformBioanalytical SystemsOutperform Votes12838.79% Underperform Votes20261.21% Eloxx PharmaceuticalsOutperform Votes1343.33% Underperform Votes1756.67% Do analysts rate BASI or ELOX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioanalytical Systems 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AEloxx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A SummaryEloxx Pharmaceuticals beats Bioanalytical Systems on 7 of the 12 factors compared between the two stocks. Ad Porter & CompanyUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Eloxx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELOX vs. The Competition Export to ExcelMetricEloxx PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1,000.00$3.14B$5.40B$8.53BDividend YieldN/A1.77%5.15%4.14%P/E Ratio0.0012.02113.7615.14Price / SalesN/A332.371,483.0493.53Price / CashN/A148.6339.7134.04Price / Book0.004.024.665.01Net Income-$36.06M-$42.25M$119.06M$225.46M7 Day PerformanceN/A8.08%0.79%0.37%1 Month PerformanceN/A8.72%5.65%3.57%1 Year PerformanceN/A32.11%36.80%29.42% Eloxx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELOXEloxx PharmaceuticalsN/A$0.00flatN/A-100.0%$1,000.00N/A0.0018BASIBioanalytical SystemsN/A$1.71+1.8%N/A-4.8%$19.03M$60.47M-4.07397Analyst ForecastPIRSPieris Pharmaceuticals2.3762 of 5 stars$16.94-0.4%N/A-14.4%$22.36M$42.81M-0.91140Gap DownLUNALuna Innovations2.0231 of 5 stars$1.81+1.7%$8.00+342.0%-70.9%$61.47M$109.50M-22.63337Analyst ForecastPGENPrecigen4.3105 of 5 stars$0.85-5.6%$7.00+723.5%-23.7%$214.85M$6.22M-1.57202Positive NewsAVXLAnavex Life Sciences3.4845 of 5 stars$5.24-1.7%$40.00+663.4%+21.6%$443.52MN/A-10.4840News CoverageGap UpAMGNAmgen4.5972 of 5 stars$316.98+0.4%$332.55+4.9%+22.4%$170.04B$30.93B54.5626,700Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst RevisionGILDGilead Sciences4.9348 of 5 stars$89.00+0.2%$86.85-2.4%+11.6%$109.76B$27.12B108.5418,000Upcoming EarningsAnalyst ForecastARGXargenx2.561 of 5 stars$556.83+1.0%$550.44-1.1%+20.4%$33.09B$1.62B-158.191,148Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageBIIBBiogen4.8398 of 5 stars$181.69-1.2%$271.39+49.4%-27.5%$26.46B$9.84B22.887,570Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageBNTXBioNTech2.1688 of 5 stars$110.48-1.1%$135.54+22.7%+19.3%$26.26B$2.69B-48.886,133Upcoming Earnings Related Companies and Tools Related Companies Bioanalytical Systems Competitors Pieris Pharmaceuticals Competitors Luna Innovations Competitors Precigen Competitors Anavex Life Sciences Competitors Amgen Competitors Gilead Sciences Competitors argenx Competitors Biogen Competitors BioNTech Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELOX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELOX Stock Alerts